Article Details
Retrieved on: 2024-05-14 20:07:33
Tags for this article:
Click the tags to see associated articles and topics
Summary
Taysha Gene Therapies Inc. is progressing with its TSHA-102 gene therapy under regenerative medicine, conducting low and high dose clinical trials with FDA's RMAT designation, which could potentially transform treatment for Rett syndrome.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here